ARCT

#3601
Arcturus Therapeutics Holdings Inc. - Common Stock
7.9 3 USD
+0.13%
Setor: Cuidados de saúde
Base: USD
Moeda do lucro: USD
Faixa diária
7.88
7.98
Faixa anual
5.86
24.14
Mudança diária
+0.13%
Mudança mensal
-5.26%
Mudança em 6 meses
+17.83%
Mudança anual
-37.21%
Fechamento anterior
7.9 2
Open
7.9 3
Mínimo
7.8 8
High
7.9 8
Volume
70
Abrir gráfico completo Full chart

Financials

Visão geral Relatórios Estatísticas
Trimestral Ano
  • Market Capitalization 225.39 M
  • Employee 111
  • Founded 2013
  • CEO Joseph E. Payne
  • Website www.arcturusrx.com
  • Headquarter Delaware, United States
  • FIGI BBG00NNW8JK1
  • Industry Biotecnologia
Receita total
Lucro líquido
Lucro básico por ação
Dívida total
Fluxo de caixa livre
Caixa e equivalentes de caixa
Índice preço/lucro
-2.55
Índice preço/fluxo de caixa
2.05

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA. The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. Vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025.

Notícias